海泰新光跌2.14%，成交额4300.69万元，近5日主力净流入-1216.52万

Core Viewpoint - The company, Qindao Haitai New Light Technology Co., Ltd., is experiencing a decline in stock price while benefiting from the depreciation of the RMB and its status as a "specialized, refined, distinctive, and innovative" enterprise in the medical device sector [1][2][3]. Company Overview - Qindao Haitai New Light was established on June 11, 2003, and went public on February 26, 2021. The company specializes in the research, development, production, and sales of medical endoscope devices and optical products [7]. - The revenue composition includes 64.86% from medical endoscope devices, 21.63% from optical products, 13.09% from maintenance services, and 0.42% from leasing [7]. Financial Performance - For the period from January to September 2025, the company achieved a revenue of 448 million yuan, representing a year-on-year growth of 40.47%. The net profit attributable to the parent company was 136 million yuan, with a year-on-year increase of 40.03% [7]. - The company has distributed a total of 277 million yuan in dividends since its A-share listing, with 207 million yuan distributed over the past three years [8]. Market Position and Trends - The company has a significant overseas revenue share of 69.12%, benefiting from the depreciation of the RMB [3]. - It has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title in China for companies excelling in niche markets and possessing strong innovation capabilities [3]. Stock Performance - On November 21, the stock price of Haitai New Light fell by 2.14%, with a trading volume of 43.0069 million yuan and a turnover rate of 0.79%, resulting in a total market capitalization of 5.417 billion yuan [1]. - The average trading cost of the stock is 46.61 yuan, with the stock currently near a resistance level of 45.45 yuan, indicating potential for a price correction if this level is not surpassed [6].